SCM
TOVX icon

Segantii Capital Management’s Theriva Biologics TOVX Stock Holding History

Segantii Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-12
Closed -$242K – 113
2016
Q1 		$242K Buy
+12
New +$180K 0.1% 58

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Segantii Capital Management's TOVX Position: Q2 2016 in Review

Segantii Capital Management sold out of Theriva Biologics (TOVX) in Q2 2016, closing a stake of 12 shares — an estimated $242K sold.

Segantii Capital Management first reported a position in TOVX in Q1 2016 and held it in 1 quarter. The position peaked at $242K in Q1 2016. 61 funds tracked by Wall St. Rank hold TOVX as of Q2 2016.

  • Segantii Capital Management reported no remaining Theriva Biologics position as of Q2 2016 after selling out during the quarter.
  • Segantii Capital Management sold 12 Theriva Biologics shares in Q2 2016, an estimated $242K.
  • Segantii Capital Management first reported a position in Theriva Biologics in Q1 2016 and held it in 1 quarter.
  • Segantii Capital Management's Theriva Biologics position peaked at $242K in Q1 2016.
  • 61 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2016.

Based on Segantii Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.